Clinical Trial Update: MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (JASPIS-01) evaluating MEN1703 (SEL24) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• MEN1703 (SEL24) (SEL24)

Snippet

Sponsor: Ryvu Therapeutics SA | Conditions: Non-Hodgkin Lymphoma, B-cell | Phase 2 | Status: RECRUITING